168986-49-0

Basic information

• Product Name: Methyl 4-piperidineacetate
• Synonyms: 2-(1-Methylpiperidin-4-yl)acetate;4-Piperidine acetic acid methyl ester hydrochloride salt;Methyl 4-piperidineacetate hydrochloride salt;Piperidin-4-yl-acetic acid methyl ester hydrochloride salt≥ 97%;METHYL 4-PIPERIDINEACETATE;4-PIPERIDINE ACETIC ACID METHYL ESTER;PIPERIDIN-4-YL-ACETIC ACID METHYL ESTER;Methyl piperidin-4-ylacetate
• CAS NO: 168986-49-0
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Product Categories: Acids and Derivatives;Amines and Anilines;Piperidines, Piperidones, Piperazines;pharmacetical;Organic acids
• Mol File: 168986-49-0.mol

Chemical Properties

• Boiling Point: 213.1 °C at 760 mmHg
• Flash Point: 82.7 °C
• Appearance: /
• Density: 0.982 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.40±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-piperidineacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-piperidineacetate(168986-49-0)
• EPA Substance Registry System: Methyl 4-piperidineacetate(168986-49-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 168986-49-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H15NO2/c1-9-4-2-7(3-5-9)6-8(10)11/h7H,2-6H2,1H3,(H,10,11)/p-1

Upstream product

• 67-56-1 methanol 
• 256411-39-9 tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate 
• 158407-04-6 tert-butyl 4-(bromomethyl)piperidine-1-carboxylate 
• 69719-84-2 4-(bromomethyl)piperidine 
• 29800-89-3 methyl 4-pyridineacetate 
• 28356-58-3 pyridine-4-acetic acid 
• 51052-78-9 4-piperidinylacetic acid 

Downstream Products

• 754183-67-0 (1-isopropylpiperidin-4-yl)acetic acid 
• 952934-82-6 C₁₃H₁₇NO₄ 
• 1620075-72-0 C₂₇H₃₁N₃O₄S 
• 1103310-81-1 [1-(2-diphenylamino-ethyl)-piperidin-4-yl]-acetic acid methyl ester 
• 1103310-17-3 C₃₁H₃₂N₄O₃S 
• 1103310-69-5 [1-(3,3-diphenyl-propyl)-piperidin-4-yl]-acetic acid methyl ester 
• 1085842-32-5 [1-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-piperidine-1-carbonyl)-piperidin-4-yl]-acetic acid methyl ester 
• 885126-06-7 1-(phenethylaminocarbonyl)-4-(methoxycarbonylmethyl)-piperidine 

Relevant articles and documents

BROAD SPECTRUM ANTI-CANCER COMPOUNDS

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors. A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition. Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells.

Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents

C9-Substituted phenanthrene-based tylophorine derivatives (PBTs) (13-36) were synthesized and evaluated as in vitro anticancer agents against the human A549 lung cancer cell line. Twelve active compounds were further examined against DU-145 (prostate), ZR-751 (breast), KB (nasopharyngeal), and KB-Vin (multidrug resistant KB subline) human cancer cell lines. They showed potent cytotoxic activity against both wild type and matched multidrug resistant KB cell lines, and displayed notable selectivity toward DU-145 (prostate) and ZR-751 (breast) cancer cell lines. The mode of action of this class may be distinctly different from that of other cancer chemotherapeutic compounds. Three PBT analogs were also evaluated in a murine model. Compound 24b showed modest in vivo antitumor activity against human A549 xenograft in nude mice as well as potent in vitro cytotoxic activity, and thus, is a promising anticancer lead compound.

ACTIVE KETONE INHIBITORS OF TRYPTASE

The present invention related to certain active tetracyclic ketone inhibitors of tryptase, pharmaceutical composition comprising these compounds and methods of treating asthma, allergic rhinitis, and/or Chronic Obstructive Pulmonary Disease utilizing thes

Development of new non-peptide GPIIb-IIIa antagnosts, NSL-95315 and NSL-95317, isosteres of NSL-95300

The synthetic and structure-activity relationship (SAR) studies of new non-peptide GPIIb/IIIa antagonists (1a-f and 3) were conducted by replacing one amide bond of NSL-95300 (2) with an (E)-double bond or an enone group. NSL-95315 (1a) and NSL-95317 (3) showed the inhibitory activity for collagen-induced human platelet aggregation with IC50 values of 0.25 μM and 0.21 μM, respectively.